{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:25:54Z","timestamp":1788297954786,"version":"build-2803163510"},"reference-count":51,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction Biology"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The 2018 European Union (EU) approved weekly and monthly subcutaneous buprenorphine depot injection (BUP\u2010XR), for opioid substitution medication proved to offer some specific treatment benefits. The present study examines the process of switching from buprenorphine sublingual tablets (BUP\u2010SL) to BUP\u2010XR from a patient's point of view. In total, nine patients were surveyed by means of an open\u2010answer questionnaire regarding course and side effects of the medication switch. Six of these patients were surveyed in more detail under BUP\u2010SL, as well as 4 and 16\u2009weeks after the switch to BUP\u2010XR by means of a test battery of questions on socio\u2010demography, withdrawal symptoms, craving, physical well\u2010being, treatment satisfaction and concomitant use of illegal substances. Patients reported significant worse physical well\u2010being and lower treatment satisfaction in 4\u00a0weeks compared with 16\u2009weeks after the medication switch to the BUP\u2010XR. Furthermore, they reported significant more frequent co\u2010use of illicit drugs, worse physical well\u2010being, lower treatment satisfaction and more craving experience 4\u00a0weeks after the switch compared with the treatment under BUP\u2010SL. Patients 16\u2009weeks under BUP\u2010XR reported significant more illicit co\u2010use and lower treatment satisfaction compared with patients under BUP\u2010SL. Connections between therapy dissatisfaction, physical discomfort, experienced craving and drug co\u2010consumption were discovered. In the first weeks after the medication switch, patients experience potentially distressing symptoms, which, however, seem to diminish over time. Close supervision and comprehensive patient education on possible burdens of the medication switch to the BUP\u2010XR might prevent unfavourable treatment courses and premature therapy dropouts.<\/jats:p>","DOI":"10.1111\/adb.13275","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T13:35:53Z","timestamp":1681997753000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4512-5283","authenticated-orcid":false,"given":"Stephanie Paula Elisabeth","family":"Guillery","sequence":"first","affiliation":[{"name":"Clinic for Psychiatry and Psychotherapy Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin  Berlin Germany"},{"name":"Department of Psychology MSB \u2013 Medical School Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Reiners","sequence":"additional","affiliation":[{"name":"KMV Krankenhaus des Ma\u00dfregelvollzugs Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Fahrner","sequence":"additional","affiliation":[{"name":"Touro College Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Enge","sequence":"additional","affiliation":[{"name":"Department of Psychology MSB \u2013 Medical School Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hellweg","sequence":"additional","affiliation":[{"name":"Clinic for Psychiatry and Psychotherapy Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen","family":"Kunte","sequence":"additional","affiliation":[{"name":"MSH \u2013 Medical School Hamburg  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golo","family":"Kronenberg","sequence":"additional","affiliation":[{"name":"Psychiatrisches Universit\u00e4tsklinikum Z\u00fcrich  Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"European drug report 2017: trends and development","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2017"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002209"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215\u20100366(15)00366\u20101"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000496112"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7006a4"},{"key":"e_1_2_10_8_1","first-page":"149","article-title":"The news on the street: prescription drugs on the black market","volume":"159","author":"Goldman B","year":"1998","journal-title":"Can Med Assoc"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(04)17630\u20107"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.301049"},{"key":"e_1_2_10_11_1","volume-title":"Overdose death rates","author":"National Institute on Drug Abuse","year":"2022"},{"key":"e_1_2_10_12_1","volume-title":"Buprenorphine: buprenorphine is an opioid medication used to treat pain and opioid addiction","author":"Centre for Addiction and Mental Health (CAMH)","year":"2016"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2019.1649252"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1191\/0269216306pm1126oa"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376\u20108716(03)00056\u20105"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08725"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000514192"},{"key":"e_1_2_10_18_1","volume-title":"Buvidal (buprenorphine): an overview of Buvidal and why it is authorised in the EU","author":"European Medicines Agency","year":"2018"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.05.007"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)32259\u20101"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010019\u20100137\u20105"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S311674"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952998709001515"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20103\u2010642\u201013760\u20100"},{"key":"e_1_2_10_25_1","volume-title":"In search of a universal drug craving scale","author":"Somoza E","year":"1995"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11469\u2010020\u201000313\u20100"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12894"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10979\u2010005\u20106832\u20107"},{"key":"e_1_2_10_29_1","volume-title":"Buprenorphine \u2010 long acting injectable","author":"Alcohol and Drug Foundation","year":"2021"},{"key":"e_1_2_10_30_1","volume-title":"Drugs and supplements buprenorphine (transdermal route)","author":"MAYO CLINIC","year":"2022"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010016\u20100472\u20109"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004145"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.10.002"},{"key":"e_1_2_10_36_1","volume-title":"Switching from methadone to Subutex: benefits and risks","author":"Addiction Resource","year":"2021"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000396"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952991003736371"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.01.008"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139942"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011\u2010022\u201000474\u20102"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/16066350109141769"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360\u20100443.2001.967104914.x"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/14659890600594070"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954\u2010019\u20100296\u20104"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010019\u201001101\u20106"},{"key":"e_1_2_10_47_1","volume-title":"Um Arztpraxen zu entlasten: Drogenbeauftragte will mehr Methadon ausgeben","author":"Szent\u2010Ivanyi T.","year":"2020"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380\u2010020\u201000880\u20107"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.06.007"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108781"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1559\u20101816.2000.tb02462.x"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.03.021"}],"container-title":["Addiction Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/adb.13275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T23:10:35Z","timestamp":1692659435000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/adb.13275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/adb.13275"],"URL":"https:\/\/doi.org\/10.1111\/adb.13275","archive":["Portico"],"relation":{},"ISSN":["1355-6215","1369-1600"],"issn-type":[{"value":"1355-6215","type":"print"},{"value":"1369-1600","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"2022-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13275"}}